This inventor holds 1 USPTO granted patent and 3 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Biocryst Pharmaceuticals, Inc.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: The Innovations of Andrew E. Spaulding
Introduction
Andrew E. Spaulding is a notable inventor based in Hoover, Alabama. He has made significant contributions to the field of pharmaceuticals, particularly in the area of complement system inhibitors. His work is essential for developing treatments for diseases characterized by aberrant complement system activity.
Latest Patents
Andrew E. Spaulding holds a patent for "Oral complement factor D inhibitors." This patent discloses compounds of formula (I) and pharmaceutically acceptable salts that act as inhibitors of the complement system. The patent also includes pharmaceutical compositions comprising such compounds and methods for using them in the treatment or prevention of related diseases.
Career Highlights
Andrew is currently associated with BioCryst Pharmaceuticals, Inc., where he continues to innovate in the pharmaceutical industry. His work focuses on developing new therapies that can significantly impact patient care.
Collaborations
He has collaborated with notable colleagues, including Pravin L. Kotian and Yarlagadda Sudhakara Babu, to advance research and development in his field.
Conclusion
Andrew E. Spaulding's contributions to the pharmaceutical industry through his innovative patents and collaborations highlight his commitment to improving healthcare solutions. His work continues to pave the way for advancements in treating complex diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile